Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
7 papers
Recent·Most cited
S. Lusvarghi, C. B. Stauft, R. Vassell…·C. D. Weiss
This study compares how N-glycan modifications affect spike expression, infectivity, and antibody neutralization in SARS-CoV-2 D614G and Omicron variants.
S. N. Neerukonda, R. Wang, R. Vassell…·W. Wang
This study characterizes the entry mechanisms and antibody neutralization resistance of Omicron variants BA.1, BA.1.1, BA.2, and BA.3 compared to the D614G strain.
S. Lusvarghi, S. D. Pollett, S. N. Neerukonda…·C. D. Weiss
A third dose of Pfizer/BioNTech vaccine significantly boosts Omicron neutralizing antibodies, while convalescent sera and therapeutic antibodies show variable and often low neutralization.
S. N. Neerukonda, R. Vassell, S. Lusvarghi…·W. Wang
This study evaluates the neutralization resistance and spike protein properties of SARS-CoV-2 B.1.617 variants, finding modest resistance to sera and therapeutic antibodies, but enhanced cleavage and fusogenic activity in Delta variants.
S. Lusvarghi, W. Wang, R. Herrup…·C. D. Weiss
The paper evaluates resistance of 25 therapeutic antibodies to SARS-CoV-2 variants with multiple spike substitutions, finding key substitutions predict resistance but other substitutions can modify it unpredictably.
S. Rothenberger, D. L. Hurdiss, M. Walser…·Vassell
This paper describes ensovibep, a trispecific DARPin that inhibits SARS-CoV-2 variants by targeting the spike protein, showing potent antiviral activity and protection in animal models.
S. N. Neerukonda, R. Vassell, R. Herrup…·C. D. Weiss
The paper establishes a SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells expressing ACE2 and TMPRSS2, showing good correlation with other assays.